EFRELand Brandenburgbe Berlin

Health Tourism and Prevention News

26.06.2017

Synthesis route toward albicidin, an antibiotic substance antibacterial activity against various Gram-positive and Gram-negative microorganisms

Due to the increasing development of antibiotic resistances by bacterial pathogens, there is a tremendous need for the development of new antibiotic lead structures. Major causes of concern are hereby Gram-negative bacteria as...► Read more ...

26.06.2017

Photoactivatable, mussel-based bioadhesives suitable for treatment of bone fractures and wound healing

In medicine, there is a long-standing demand for biocompatible glues, which can be applied for the treatment of bone fractures or accelerated wound healing. Biocompatible bio-glues must meet several demands, such as good binding...► Read more ...

26.06.2017

Novel knee brace which solves the nonconformance/ incongruity problem between knee and orthotic

Knee brace migration is a common problem which can affect compliance and possibly even device effectiveness. Key to minimizing knee brace migration is making sure the device fits the patient’s anatomy as closely as...► Read more ...

22.06.2017

NMI TT Pharmaservices and Charité awarded grant for development of protein profiling for individualization of tumor therapy

Contract research provider NMI TT Pharmaservices and Charité Universitätsmedizin Berlin today announced that they have been awarded a research grant for development of a multiplex protein profiling based platform that aims to...► Read more ...

21.06.2017

Isansys Lifecare opens European headquarters in Brandenburg-Berlin Cluster

Isansys Lifecare, the leader in new generation wireless patient monitoring systems, today announces the establishment of Isansys Lifecare Europe GmbH. ► Read more ...

21.06.2017

Myelo Therapeutics conducts successful Pre-IND meeting with U.S. Food and Drug Administration (FDA) for Myelo001 and completes new financing round

Myelo Therapeutics GmbH announced that it successfully conducted a Pre-IND (Investigational New Drug) meeting with the FDA Center for Drug Evaluation and Research (CDER) on May 11th, 2017 for Myelo001, a novel, orally...► Read more ...

19.06.2017

Omalizumab shown to be effective in treating inducible urticaria

Patients who develop itchy wheals in response to cold or friction benefit from treatment with omalizumab, a drug normally used to treat asthma. Two separate clinical studies, conducted by researchers from Charité –...► Read more ...

15.06.2017

Thanares GmbH Awarded US-Patent for Novel Preparations of Tartary Buckwheat with Health Benefits

Thanares GmbH, the R&D biotechnology company in the field of phytochemicals, announced the issue by the U.S. Patent and Trademark Office on April. 11, 2017 of a new patent about its novel preparation of tartary buckwheat. ► Read more ...

15.06.2017

OMEICOS Secures Continued BMBF Support with New €1.7M Research Grant to Advance its Novel Approach to Treat Cardiovascular Diseases

Clinical Trial in Atrial Fibrillation Ongoing as OMEICOS Evaluates Therapeutic Paradigm in Additional Indication Areas► Read more ...